Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis

NCT03342807 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2017-11-17

No results posted yet for this study

Summary

To investigate an economical and effective way to reduce the level of serum triglyceride in patients with hypertriglyceridemia-induced acute pancreatitis.

Conditions

  • Pancreatitis, Acute
  • Hypertriglyceridemia

Interventions

DRUG

Insulin

Insulin infusion for subjects in Group Insulin.

DEVICE

Aphesis

Aphesis for subjects in Group Aphesis.

Sponsors & Collaborators

  • First Hospitals affiliated to the China PLA General Hospital

    collaborator OTHER_GOV
  • Nanjing General Hospital

    collaborator UNKNOWN
  • Fujian Provincial Hospital Emergency Center

    collaborator UNKNOWN
  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER
  • Jinhua Central Hospital

    collaborator OTHER
  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER
  • Tianjin Medical University General Hospital

    collaborator OTHER
  • The First Hospital of Hebei Medical College

    collaborator UNKNOWN
  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER
  • Shenzhen Baoan District People 's Hospital

    collaborator UNKNOWN
  • The General Hospital of Shenyang Military

    collaborator UNKNOWN
  • Cangzhou Center Hospital

    collaborator UNKNOWN
  • Wuxi Third People 's Hospital

    collaborator UNKNOWN
  • General Hospital of Ningxia Medical University

    collaborator OTHER
  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-11-30
Completion
2020-11-30
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03342807 on ClinicalTrials.gov